FOXK2

Across TCGA pan-cancer cohorts, FOXK2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FOXK2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FOXK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FOXK2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where FOXK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.870	0.613	<.001	34	view →
LSCC	OS	Median	All	0.883	0.694	.010	12	view →
PDAC	DFS	Quartile	III,IV	0.218	0.601	.017	11	view →
LUAD	DFS	Quartile	II,III,IV	0.727	0.372	.026	3	view →
HNSC	OS	Quartile	IV	0.554	0.891	.012	2	view →
GBM	DFS	Quartile	All	0.374	0.231	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FOXK2–CCRCC (DFS)

Open the CCRCC breakdown →